Ine Vanderleyden - August 9, 2023 The next-generation therapies for autoimmune diseases The immune system has an extraordinary capacity to distinguish “self” from “non-self”. This means ...
Ine Vanderleyden - February 20, 2023 Trafficking T cells – how to get cells to their target destination After being in the shadow of its famous relative, the antibody-producing B cell, for many decades, ...
Ine Vanderleyden - May 6, 2022 Replacing the bad with the good – an IP perspective on microbial consortia Our body hosts trillions of microorganisms that are essential to many aspects of human health. This ...
Frances Salisbury - September 10, 2020 Neoantigens: IP considerations for an emerging class of cancer immunotherapy Recent cell and gene therapy product approvals have allowed the pharmaceutical industry to start a ...
Ine Vanderleyden - March 31, 2020 Neoantigen-targeted adoptive cell therapies – the next frontier in cancer immunotherapy Cancer immunotherapies harness the power of the patient’s immune system to destroy malignant cells ...